Achilles Therapeutics plc
ACHL · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.12 | 0.03 | -0.01 | 0.21 |
| FCF Yield | -139.43% | -190.34% | -46.61% | -5.52% |
| EV / EBITDA | 1.30 | 1.92 | 1.82 | -15.49 |
| Quality | ||||
| ROIC | -51.21% | -38.01% | -21.24% | -16.37% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.69 | 0.84 | 0.97 | 0.76 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 26.10% | -0.19% | -80.38% | -145.95% |
| Safety | ||||
| Net Debt / EBITDA | 1.80 | 2.45 | 4.18 | 4.91 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.80 | 0.64 | 0.00 |
| Cash Conversion Cycle | -434.26 | -55.72 | 156.65 | -2,962.20 |